Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Adverum Biotechnologies	Mesoblast	Taysha Gene Therapies	Cortexyme	Coherus BioSciences
Symbol	NASDAQ:ADVM	NASDAQ:MESO	NASDAQ:TSHA	NASDAQ:CRTX	NASDAQ:CHRS
Price Information
Current Price	$9.02	$8.64	$23.26	$35.68	$13.92
52 Week Range	Buy	Hold	Buy	Hold	Buy
MarketRank™
Overall Score	1.7	1.4	1.8	1.3	1.4
Analysis Score	3.4	3.2	3.5	3.1	3.4
Community Score	2.4	3.1	3.9	2.6	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	0.0	0.8	0.8	0.0
Earnings & Valuation Score	0.0	0.6	0.6	0.0	1.3
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Hold	Buy
Consensus Price Target	$23.50	$14.55	$43.92	$50.00	$26.50
% Upside from Price Target	160.53% upside	68.40% upside	88.81% upside	40.13% upside	90.37% upside
Trade Information
Market Cap	$882.12 million	$1.12 billion	$878.32 million	$1.05 billion	$1.01 billion
Beta	1.72	3.71	N/A	0.95	1.57
Average Volume	841,513	601,720	90,946	305,475	1,343,341
Sales & Book Value
Annual Revenue	$250,000.00	$32.16 million	N/A	N/A	$356.07 million
Price / Sales	3,528.48	34.86	N/A	N/A	2.85
Cashflow	N/A	N/A	N/A	N/A	$1.04 per share
Price / Cash	N/A	N/A	N/A	N/A	13.36
Book Value	$2.71 per share	$4.70 per share	N/A	$4.30 per share	$1.50 per share
Price / Book	3.33	1.84	N/A	N/A	9.28
Profitability
Net Income	$-64,490,000.00	$-77,940,000.00	N/A	$-36,980,000.00	$89.83 million
EPS	($1.01)	($0.74)	N/A	($1.94)	$1.23
Trailing P/E Ratio	N/A	N/A	0.00	N/A	6.82
Forward P/E Ratio	N/A	N/A	N/A	N/A	15.82
P/E Growth	N/A	N/A	N/A	N/A	9.34
Net Margins	N/A	-591.00%	N/A	N/A	33.06%
Return on Equity (ROE)	-32.23%	-18.69%	N/A	-37.78%	90.98%
Return on Assets (ROA)	-28.02%	-13.85%	N/A	-35.24%	27.33%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.10%	N/A	N/A	1.58%
Current Ratio	28.53%	1.32%	24.02%	8.71%	5.45%
Quick Ratio	28.53%	1.32%	24.02%	8.71%	5.18%
Ownership Information
Institutional Ownership Percentage	97.41%	2.80%	42.19%	55.48%	N/A
Insider Ownership Percentage	12.40%	18.80%	N/A	19.80%	15.86%
Miscellaneous
Employees	167	102	38	37	317
Shares Outstanding	97.80 million	129.74 million	37.76 million	29.55 million	72.79 million
Next Earnings Date	5/27/2021 (Estimated)	5/26/2021 (Estimated)	6/2/2021 (Estimated)	5/11/2021 (Estimated)	5/6/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	The Market Doesn't Like What It Sees From Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Earnings Yet nasdaq.com - April 13 at 9:23 AM
	Coherus BioSciences Sees Unusually Large Options Volume (NASDAQ:CHRS) americanbankingnews.com - April 13 at 7:18 AM
	Coherus BioSciences (NASDAQ:CHRS) Reaches New 12-Month Low at $13.70 americanbankingnews.com - April 12 at 11:08 AM
	Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Buy" by Brokerages americanbankingnews.com - April 10 at 9:08 AM
	Head to Head Comparison: Forma Therapeutics (NASDAQ:FMTX) vs. Coherus BioSciences (NASDAQ:CHRS) americanbankingnews.com - April 8 at 12:26 AM
	Coherus BioSciences (NASDAQ:CHRS) Stock Price Up 3.7% americanbankingnews.com - April 7 at 12:30 PM
	Coherus BioSciences (NASDAQ:CHRS) Hits New 52-Week Low at $14.00 americanbankingnews.com - April 5 at 1:28 PM
	Coherus BioSciences (NASDAQ:CHRS) Stock Rating Upgraded by Zacks Investment Research marketbeat.com - April 2 at 7:13 PM
	Brokerages Anticipate Coherus BioSciences, Inc. (NASDAQ:CHRS) to Announce $0.09 Earnings Per Share americanbankingnews.com - March 31 at 6:28 PM
	Coherus BioSciences (NASDAQ:CHRS) Reaches New 12-Month Low at $14.02 americanbankingnews.com - March 30 at 12:42 PM
	I Ran A Stock Scan For Earnings Growth And Coherus BioSciences (NASDAQ:CHRS) Passed With Ease finance.yahoo.com - March 23 at 7:27 AM
	Financial Survey: Champions Oncology (NASDAQ:CSBR) versus Coherus BioSciences (NASDAQ:CHRS) americanbankingnews.com - March 20 at 7:56 AM
	Coherus announces start of rolling submission of Toripalimab marketing application seekingalpha.com - March 5 at 8:01 AM
	Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for ... apnews.com - March 3 at 9:31 AM
	Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma finance.yahoo.com - March 3 at 9:30 AM
	Coherus Management to Present at Upcoming Investor Conferences finance.yahoo.com - February 25 at 1:13 PM
	Coherus BioSciences Inc (CHRS) Q4 2020 Earnings Call Transcript finance.yahoo.com - February 25 at 1:46 AM
	Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue Estimates nasdaq.com - February 24 at 8:45 PM
	Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - February 24 at 8:45 PM
	Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to Decline nasdaq.com - February 19 at 9:23 AM
	Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th finance.yahoo.com - February 18 at 8:39 AM
	Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review markets.businessinsider.com - February 17 at 9:08 AM
	Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review finance.yahoo.com - February 17 at 9:08 AM
	Coherus Announces CFO Transition Plans finance.yahoo.com - February 16 at 8:49 AM
	Did Coherus BioSciences' (NASDAQ:CHRS) Share Price Deserve to Gain 89%? finance.yahoo.com - February 6 at 9:39 AM
	China’s Junshi Jumps After Licensing Cancer Drug to Coherus in USD1.11 Billion Deal yicaiglobal.com - February 4 at 2:36 PM

Date	Company	Brokerage	Action
3/2/2021	Adverum Biotechnologies	Cantor Fitzgerald	Reiterated Rating
12/15/2020	Adverum Biotechnologies	UBS Group	Initiated Coverage
11/12/2020	Adverum Biotechnologies	Raymond James	Upgrade
11/5/2020	Adverum Biotechnologies	Lifesci Capital	Reiterated Rating
8/11/2020	Adverum Biotechnologies	SVB Leerink	Boost Price Target
8/10/2020	Adverum Biotechnologies	Piper Sandler	Boost Price Target
6/16/2020	Adverum Biotechnologies	Royal Bank of Canada	Boost Price Target
5/30/2020	Adverum Biotechnologies	Chardan Capital	Reiterated Rating
5/5/2020	Adverum Biotechnologies	SunTrust Banks	Upgrade
4/28/2020	Adverum Biotechnologies	The Goldman Sachs Group	Initiated Coverage
1/13/2020	Adverum Biotechnologies	Piper Jaffray Companies	Boost Price Target
4/13/2021	Mesoblast	Maxim Group	Upgrade
1/19/2021	Mesoblast	Jefferies Financial Group	Downgrade
12/15/2020	Mesoblast	HC Wainwright	Reiterated Rating
5/28/2020	Mesoblast	LADENBURG THALM/SH SH	Boost Price Target
12/19/2019	Mesoblast	Dawson James	Initiated Coverage
9/10/2019	Mesoblast	Oppenheimer	Set Price Target
4/13/2021	Taysha Gene Therapies	Morgan Stanley	Boost Price Target
3/1/2021	Taysha Gene Therapies	William Blair	Initiated Coverage
12/11/2020	Cortexyme	Smith Barney Citigroup	Initiated Coverage
12/11/2020	Cortexyme	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
12/7/2020	Cortexyme	Bank of America	Upgrade
5/13/2020	Cortexyme	Canaccord Genuity	Reiterated Rating
6/3/2019	Cortexyme	Credit Suisse Group	Initiated Coverage
6/3/2019	Cortexyme	JMP Securities	Initiated Coverage
11/19/2020	Coherus BioSciences	Mizuho	Lower Price Target
2/6/2020	Coherus BioSciences	JPMorgan Chase & Co.	Boost Price Target
8/12/2019	Coherus BioSciences	Barclays	Set Price Target

(Data available from 4/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources